NCT02021240

Brief Summary

Low dose sub-anaesthetic dose of ketamine has been shown to reduce postoperative pain and analgesic consumption. However, due to the heterogeneous results, the standard dosing regimen has not been available. Recently, its effect in postoperative outcomes and the development of post-operative surgical pain has also been suggested. Ketamine has been shown to reduce post-operative early inflammation especially serum IL-6. Therefore, study in its effects in post- operative pain and outcomes due to inflammation is suggested. Only few clinical studies assessed post-operative pain are related to inflammation. Pain after third molar surgery is a good model of postoperative acute inflammatory pain. A previous study showed that there was no benefit to administer ketamine before or after oral surgery for pain relief. However, other studies demonstrated that ketamine used as sedative or local ketamine in third molar surgery could reduce postoperative dental pain, swelling and trismus. Postsurgical facial oedema is difficult to quantify accurately as it is three dimensional. Over the years, various measurement techniques have been tried to measure oedema objectively. These include direct linear measurement using tape or flexible rulers across fixed soft tissue landmarks, standardized stereophotographic measurements, computerized tomography (CT), magnetic resonance imaging (MRI), ultrasonography (US) and three - dimensional (3D) laser scanning. Recently, three dimensional image reconstructions using a reversed engineering technique has been developed and is used in the manufacturing industry. This technology could be applied in a clinical setting for monitoring soft tissue changes. In this study, the investigators will aim to study the use of sub-anaesthetic dose of ketamine in post-operative dental pain and recovery outcomes. The investigators hypothesise that post-operative pain after Bilateral Third Molar under General Anaesthesia is less in patients receiving sub-anaesthetic does of ketamine before incision. The magnitude of this effect will be compared with a positive control group (dexamethasone) as well as a placebo group (normal saline). Further, the investigators aim to demonstrate whether ketamine can reduce post-operative facial oedema and other post-operative outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for phase_3 postoperative-pain

Timeline
Completed

Started Feb 2014

Typical duration for phase_3 postoperative-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 11, 2013

Completed
16 days until next milestone

First Posted

Study publicly available on registry

December 27, 2013

Completed
2 months until next milestone

Study Start

First participant enrolled

February 10, 2014

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 18, 2015

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 18, 2016

Completed
Last Updated

November 9, 2020

Status Verified

November 1, 2020

Enrollment Period

1.6 years

First QC Date

December 11, 2013

Last Update Submit

November 5, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pain scores as numerical rating scale after operation

    Every 15 minutes for 1 hour after operation, every 4 hourly at the first 24 hour after operation, and at postoperative 48th and 72rd hour

Secondary Outcomes (3)

  • Facial oedema measured by using 3D laser scanning of the face

    Before operation and at post-operative day1 and day 2

  • Number of patients having adverse effects

    Postoperative day 1 to day 3

  • Serum IL-6 and TNF - α

    Before operation and at postoperative 6th and 16th hour

Study Arms (3)

Ketamine

ACTIVE COMPARATOR

Single dose of intravenous ketamine 0.5mg/kg before incision

Drug: Ketamine

Dexamethasone

ACTIVE COMPARATOR

Single dose of intravenous dexamethasone 8mg before incision

Drug: Dexamethasone

Normal saline

PLACEBO COMPARATOR

Single dose of intravenous normal saline before incision

Drug: Normal Saline

Interventions

Ketamine
Dexamethasone
Normal saline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA I and II
  • Bilateral wisdom teeth extraction under general anaesthesia
  • Age over 18
  • Written informed consent

You may not qualify if:

  • Allergy to ketamine or dexamethasone
  • Patient refusal
  • Pregnancy
  • Alcohol or drug abuse
  • Known impaired renal function and liver function

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oral and Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong

Hong Kong, 0000, Hong Kong

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

KetamineDexamethasoneSaline Solution

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

CyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, FluorinatedCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Chi Wai Cheung

    Department of Anaesthesiology, Queen Mary Hospital, Hong Kong

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

December 11, 2013

First Posted

December 27, 2013

Study Start

February 10, 2014

Primary Completion

September 18, 2015

Study Completion

April 18, 2016

Last Updated

November 9, 2020

Record last verified: 2020-11

Locations